Sex: F
Vaccine: HPV4
Symptoms: Uterine haemorrhage
Clinical narrative: autonomic injuries; neurological disorder; hot flashes; mood swings; autoimmune injuries; Pain medicine was prescribed but did not help; endometriosis/experienced changes to her menstrual cycle, severe abdominal pain and bleeding that would not stop; adenomyosis/experienced changes to her menstrual cycle, severe abdominal pain and bleeding that would not stop; hormon replacement medication to prevent menopause; could not have another child; cyst on left and right ovaries; salpingitis; abundant intraluminal acute inflammation and salpingitis between September and November of 2022, which had spread from her uterus to her fallopian tubes; scars across abdomen; Information was received from a lawyer regarding a case in litigation and refers to an adult female (exact age not provided) patient (pt). Her medical history included benign tumors removal from her left ovary. The pt's concurrent conditions and concomitant therapies were not provided.  On 11-FEB-2022, 07-APR-2022 and 08-OCT-2022 the pt was vaccinated with the first, second and third dose of quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL) intramuscular injection respectively (exact doses, routes of administration, anatomical locations, lot # and expiration dates were not provided), as recommended by her health care provider, for prophylaxis (also reported as touted as safe and effective for preventing cervical cancer). Prior to her quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL) vaccinations, the pt was happy and healthy. Following her second quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL) vaccination, she experienced changes to her menstrual cycle. She started having severe abdominal pain and bleeding that would not stop. Her physician ordered an immediate scan of her abdominal area, performed on 23-SEP-2022. The scan showed cysts on her left and right ovaries. The pt was diagnosed with adenomyosis. Pain medicine was prescribed but did not help. Norethindrone was prescribed to stop the lining of her uterus from growing and to stop the bleeding. The pt did not know and had no reason to know that the symptoms she was experiencing were caused by the quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL) vaccine, as no such information was given to her by her medical providers. Since she had been on medication to prevent menses, the had her third quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL) vaccination before her surgery. On 03-NOV-2022, she had severe abdominal pain and had to go to the emergency room. She was told that a hysterectomy was her only solution. On 29-NOV-2022, she had a total hysterectomy, bilateral salpingectomy, left oophorectomy and cystoscopy (results not provided). After surgery, the pathology report stated that she had abundant intraluminal acute inflammation and salpingitis between September and November of 2022, which had spread from her uterus to her fallopian tubes. The only explanation was the quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL) vaccinations. As a result of the surgery, the pt at 38 years of age, needed hormone replacement medication to prevent menopause. She could not have another child. At that time, she had hot flashes, mood swings and other symptoms as well as scars across her abdomen. The pt contended that her quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL) injections caused her to develop serious and debilitating autoimmune injuries, including but not limited to adenomyosis, endometriosis, hysterectomy, intraluminal acute inflammation and salpingitis, as well as a constellation of adverse symptoms, complications, injuries, and other adverse events, many of which are alleged herein and all of which were caused by quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL) or otherwise linked to her quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL)-induced autoimmune disorder. As a proximate result of quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL), the pt suffered and continued to suffer severe and permanent physical injuries, and associated symptomology and suffered severe and permanent emotional injuries, including pain and suffering. She also had a substantial fear of suffering additional and ongoing harms, including but not limited to at that time being at an increased risk of cancer, and future symptoms and harms associated with her autoimmune disease and other injuries caused by quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL). As a direct and proximate result of her quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL)-induced injuries, the pt suffered and continued to suffer economic losses, including considerable financial expenses for medical care and treatment, and diminished income capacity and she would continue to incur these losses and expenses in the future. The outcome of drug ineffective was unknown and the outcome of the other events was considered to be not recovered.  The causality between quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL) and drug ineffective was unknown. The reporter considered the other events to be related to quadrivalent human papillomavirus (Types 6,11,16,18) recomb. vaccine (GARDASIL).  Upon internal review, events of autoimmune injuries, autonomic injuries and salpingitis were determined to be medically significant. Endometriosis and adenomyosis were considered medically significant as they were treated with total hysterectomy and bilateral salpingectomy (listed od procedural ASTL).  The reporter considered endometriosis, adenomyosis, autonomic injuries, autoimmune injuries, neurological injuries, cyst on ovaries, salpingitis, abundant intraluminal acute inflammation, scars across abdomen, hot flashes, mood swings, could not have another child and hormone replacement therapy to prevent menopause to be disabling.